Magenta Therapeutics, Inc. (MGTA) News
Magenta Therapeutics, Inc. (MGTA)
Today's Latest Price: $9.20 USD
Updated Jul 7 2:17pm
Add MGTA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter MGTA News Items
MGTA News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MGTA News From Around the Web
Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTANEW YORK, NY / ACCESSWIRE / July 6, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ... |
Magenta (MGTA) Looks Good: Stock Adds 5.2% in SessionMagenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. |
Big DraftKings Investor Bought Up an Embattled Biotech StockAn Atlas Venture affiliate just paid $10 million for more shares of Magenta Therapeutics. Atlas is also the fourth-largest shareholder in sports-betting company DraftKings. |
Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesMagenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $69.0 million. |
Magenta Therapeutics prices equity offering at $8Magenta Therapeutics (MGTA) has priced its public offering of 7.5M common shares at $8.00/share, for expected gross proceeds of $60M.Underwriters' over-allotment is an additional 1,125,000 shares. Closing date is June 29.Previously: Magenta Therapeutics announces $60M equity offering (June 24)... |
Magenta Therapeutics Announces Pricing of Public OfferingMagenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Magenta. |
Magenta Therapeutics announces $60M equity offeringMagenta Therapeutics (MGTA) to offer $60M shares in an underwritten public offering, with underwriters having an option to purchase up to an additional 15% of the shares.Price and number of shares have yet to be decided.The company plans to use the proceeds for clinical development, R&D, working capital and general... |
Magenta Therapeutics Launches Proposed Public OfferingMagenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta. |
Magenta teams up with Beam Therapeutics in blood disordersMagenta Therapeutics (MGTA) inks a non-exclusive research and clinical collaboration agreement with Beam Therapeutics (BEAM) to evaluate its antibody-drug conjugate ((ADC)) MGTA-117 for conditioning sickle cell disease and beta-thalassemia patients receiving the latter's base editing therapies.Conditioning is done to prepare a patient receiving edited cells that need to engraft in... |
Magenta bails on cell therapy in inherited metabolic disordersMaking a "strategic decision," Magenta Therapeutics (MGTA) will discontinue enrollment in a Phase 2 clinical trial evaluating MGTA-456 in patients with inherited metabolic disorders, deciding instead to focus its resources on stem cell mobilization and conditioning programs.It cites COVID-19 disruptions, a growing understanding of the challenges of allogeneic stem cell... |
